Constipation
Conditions
Keywords
Acacia gum, gummi arabicum, microbiome, short chain fatty acids, SCFA, stool frequency, stool consitency
Brief summary
Proof of concept study to investigate the impact of a food supplement consisting of Acacia gum on changes of gut microbiota and production of short chain fatty acids. Additionally, safety, tolerability and parameters of bowel function (stool frequency, stool consistency and gastrointestinal symptoms) will be assessed during the study.
Interventions
DIETARY_SUPPLEMENTacacia gum
Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
Sponsors
BioTeSys GmbH
Alpinia Laudanum GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects without clinical diagnosed diseases with relevant effect on the gastrointestinal system or on visceral motility * Constipation defined as an average of 2 - 3 stools per week (which needs to be confirmed during a prospective run-in phase) * At least one of the following criteria: * straining during more than 25% of defecations * lumpy or hard stools (Bristol Stool Form Scale 1 or 2) present more than 25% of defecations * sensation of incomplete evacuation in more than 25% of defecations * sensation of anorectal obstruction/ blockage in more than 25% of defecations * manual manoeuvre to facilitate more than 25% of defecations (such as digital evacuation or support from pelvic floor) * Criteria of constipation for at least the previous 3 months * BMI 18.5 - 30 kg/m2 * Stable body weight (+/- 5%) in the last 3 months (self-reported) * Willing to maintain normal background dietary habits & physical activity levels throughout the study period * Written consent to participate in the study
Exclusion criteria
* Relevant history or presence of any severe medical disorder, potentially interfering with this study in the investigator's judgement (e.g. mal absorption, food intolerance or allergy, chronic gastro-intestinal diseases (e.g. Morbus Crohn, Colitis Ulcerosa), chronic kidney or liver disease, severe depression, immunological disorders, severe cardiovascular disease, diabetes, acute malignant disease within last 3 years except basal cell carcinoma of the skin) * Prior abdominal surgery which may present a risk for the subject or confound the study results (according to the investigator's opinion) * Currently (or in the last 3 months) suffering from significant stress, anxiety or depression which, in the subjects opinion, interferes with normal daily life (e.g. has the subject missed days of work due to these conditions) and/or which could be responsible for gastrointestinal problems * Exclusively vegan or vegetarian diet (high fiber content) * Regular laxative use at least once per week * Use of hypolipidaemic drugs (e.g. statins, fibrates, resins, ezetimibe, niacin) * Subject under prescription for medication or taking dietary supplements possibly interfering with this study (such as anti-spasmodic, laxatives and anti-diarrheic drugs or other digestive auxiliaries, use of PPIs, bismuth salts and/or H2-antagonists, fibers etc.) within 2 weeks prior to study start or during the study; Stable medication (more than 3 months) for hypertension or thyroid gland is allowed. * Use of pre- and probiotic supplements * Subjects consuming * food or drinks claimed as 'probiotic', or 'prebiotic more than once weekly * food or drinks claimed as 'rich in fiber' (including specific milk products) more than 3 times per week * more than 3 portions of fruits and vegetables (sum) per day * Smoker * Intake of antibiotics in the last 4 weeks * Pregnancy or breastfeeding (also exclude recent pregnancy in the last 3 months). A pregnancy test will be conducted during screening and visits 1 - 3. * Currently or recently (within 3 months of study entry) taking any medication, which in the opinion of the investigator, could interfere with the outcome of the study, e.g. opioids, anti-psychotics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gut microbiota | day 1, day 43 and day 71 | Composition and diversity (Shannon index), Lactobacillogenic and bifidogenic level, Distribution of bacterial taxa at the phylum, family and genus level, Shifts of specific bacterial taxa |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stool frequency | day -14 (run-in phase) until day 70 (end of follow up) | frequency per week will be assessed via diary |
| Stool consitency | day -14 (run-in phase) until day 70 (end of follow up) | consistency will be assessed via Bristol Stool Form Scale |
| Gastrointestinal symptoms | day -14 (run-in phase) until day 70 (end of follow up) | Global Gastrointestinal Discomfort Assessment (PAC-SYM), single gastrointestinal symptoms (flatulence, rumbling (i.e. borborygmi)), layative use |
| Blood biomarker | day 1, day 43 and day 71 | Lipid profile (total, HDL- and LDL- cholesterol and triglycerides) Blood glucose Electrolytes and minerals (plasma sodium, potassium and calcium) SCFA (short chain fatty acids) (optional) Cytokines: IL-10 & IL-6 (optional) |
| Stool biomarker | day 1, day 43 and day 71 | SCFA (short chain fatty acids) Zonulin Calprotectin (optional) Secretory IgA (optional) Beta-defensin (optional) Bile acids (optional) Nitric oxide (optional) |
Countries
Germany
Outcome results
None listed